Imunon, Inc. Net Income Loss

• Imunon, Inc. showed an increase of +22.2% in Net Income Loss from 2024 to 2025.
• This data is from Imunon, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2010 to 2025), Imunon, Inc.'s Net Income Loss has grown by 23.0%.
• Historical annual values: Fiscal year 2025: -$14.50 million | Fiscal year 2024: -$18.62 million | Fiscal year 2023: -$19.51 million | Fiscal year 2022: -$35.90 million | Fiscal year 2021: -$20.77 million | Fiscal year 2020: -$21.48 million | Fiscal year 2019: -$16.85 million | Fiscal year 2018: -$11.88 million | Fiscal year 2017: -$20.40 million | Fiscal year 2016: -$22.05 million | Fiscal year 2015: -$22.46 million | Fiscal year 2014: -$25.49 million | Fiscal year 2013: -$8.25 million | Fiscal year 2012: -$26.57 million | Fiscal year 2012: -$26.57 million | Fiscal year 2011: -$23.22 million | Fiscal year 2010: -$18.82 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026